Chardan Capital Equities Analysts Increase Earnings Estimates for Taysha Gene Therapies, Inc. (NASDAQ:TSHA)

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) – Stock analysts at Chardan Capital lifted their FY2024 earnings per share (EPS) estimates for shares of Taysha Gene Therapies in a research note issued on Wednesday, August 14th. Chardan Capital analyst Y. Livshits now anticipates that the company will post earnings per share of ($0.31) for the year, up from their prior forecast of ($0.43). Chardan Capital currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Taysha Gene Therapies’ current full-year earnings is ($0.37) per share. Chardan Capital also issued estimates for Taysha Gene Therapies’ FY2025 earnings at ($0.43) EPS.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Monday, August 12th. The company reported ($0.09) EPS for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. The business had revenue of $1.11 million during the quarter, compared to analyst estimates of $3.62 million. Taysha Gene Therapies had a negative return on equity of 168.91% and a negative net margin of 888.18%. During the same period in the prior year, the firm posted ($0.38) EPS.

A number of other brokerages have also recently issued reports on TSHA. JMP Securities restated a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a research note on Thursday, June 20th. BMO Capital Markets began coverage on Taysha Gene Therapies in a report on Thursday, June 27th. They set an “outperform” rating and a $5.00 target price for the company. Canaccord Genuity Group cut their price objective on Taysha Gene Therapies from $7.00 to $6.00 and set a “buy” rating for the company in a report on Wednesday, August 14th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $8.00 target price (up previously from $2.00) on shares of Taysha Gene Therapies in a research note on Tuesday, May 14th. Finally, Piper Sandler lowered their price objective on Taysha Gene Therapies from $9.00 to $7.00 and set an “overweight” rating for the company in a research report on Monday, July 1st. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, Taysha Gene Therapies presently has a consensus rating of “Buy” and an average price target of $6.22.

Taysha Gene Therapies Trading Down 1.7 %

Shares of Taysha Gene Therapies stock opened at $2.25 on Monday. Taysha Gene Therapies has a 1 year low of $1.27 and a 1 year high of $4.32. The firm has a market cap of $420.79 million, a PE ratio of -4.59 and a beta of 0.41. The stock has a fifty day moving average price of $2.50 and a 200-day moving average price of $2.57. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.22 and a quick ratio of 3.38.

Insider Activity at Taysha Gene Therapies

In other Taysha Gene Therapies news, major shareholder Paul B. Manning acquired 1,333,333 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The shares were bought at an average cost of $2.25 per share, with a total value of $2,999,999.25. Following the completion of the transaction, the insider now directly owns 1,333,333 shares of the company’s stock, valued at approximately $2,999,999.25. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. China Universal Asset Management Co. Ltd. grew its holdings in Taysha Gene Therapies by 66.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 35,908 shares of the company’s stock valued at $103,000 after buying an additional 14,286 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of Taysha Gene Therapies in the 4th quarter worth $28,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Taysha Gene Therapies in the 4th quarter worth $31,000. Principal Financial Group Inc. bought a new position in shares of Taysha Gene Therapies in the 2nd quarter worth $48,000. Finally, Chicago Partners Investment Group LLC raised its position in shares of Taysha Gene Therapies by 21.4% in the 4th quarter. Chicago Partners Investment Group LLC now owns 134,851 shares of the company’s stock worth $239,000 after acquiring an additional 23,740 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.